0001651308-20-000003.txt : 20200102 0001651308-20-000003.hdr.sgml : 20200102 20200102160102 ACCESSION NUMBER: 0001651308-20-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200102 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200102 DATE AS OF CHANGE: 20200102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981209416 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 20501492 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 8-K 1 a8-kx02jan20.htm 8-K Document
false0001651308 0001651308 2020-01-02 2020-01-02


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 2, 2020

BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)
Cayman Islands
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
 
BGNE
 
The NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*
 
06160
 
The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o







Item 3.02  Unregistered Sales of Equity Securities.
 
The disclosure set forth under Item 8.01 regarding the share subscription is incorporated by reference into this Item 3.02.
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
The disclosure set forth under Item 8.01 regarding the appointment of the new director is incorporated by reference into this Item 5.02.

Item 7.01  Regulation FD Disclosure.
 
On January 2, 2020, BeiGene, Ltd. (the “Company”) issued a press release announcing the closing of the transactions described in this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Security Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing or this Current Report.
 
Item 8.01  Other Events.
 
Summary
On January 2, 2020, BeiGene announced the closing of its strategic collaboration with Amgen Inc. (“Amgen”) that the parties previously announced on October 31, 2019, as further described below.
 
Collaboration Agreement
As previously disclosed, on October 31, 2019, the Company and its wholly-owned subsidiary, BeiGene Switzerland GmbH (“BeiGene Switzerland”, and together with the Company, “BeiGene”), entered into a Collaboration Agreement (the “Collaboration Agreement”) with Amgen, pursuant to which BeiGene and Amgen have agreed to enter into a strategic collaboration on certain of Amgen’s oncology assets. Pursuant to the terms of the Collaboration Agreement, BeiGene will be responsible for commercializing Amgen’s oncology products XGEVA® (denosumab), KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab) in China (excluding Hong Kong, Macao and Taiwan) for a period of five or seven years following each product’s regulatory approval in China, as specified in the agreement, with the commercialization period for XGEVA® (which was recently approved in China) commencing following the transition of operational responsibilities for the product. Additionally, pursuant to the terms of the Collaboration Agreement, BeiGene and Amgen have agreed to collaborate on the global development of 20 Amgen oncology pipeline products, with BeiGene responsible for conducting development activities in China pursuant to a development plan and budget.

The foregoing descriptions of the terms of the Collaboration Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the agreement, which the Company intends to file as an exhibit to a subsequent periodic report or on an amendment to this Current Report on Form 8-K.

Concurrent with the closing of the other transactions described in this Current Report on Form 8-K and following the approval by a majority vote of the Company’s shareholders and the expiration or termination of applicable waiting periods under all applicable antitrust laws, the Collaboration Agreement became effective as of January 2, 2020 (the “Effective Date”).

Share Purchase Agreement
Concurrent with the closing of the other transactions described in this Current Report on Form 8-K and following the approval by a majority vote of the Company’s shareholders, on the Effective Date, the Company closed the sale of 206,635,013 ordinary shares in the form of 15,895,001 American Depositary Shares (“ADSs”) of the Company, representing approximately 20.5% of the Company’s outstanding shares to Amgen for an aggregate cash price of US$2.78 billion, or US$13.45 per ordinary share, or US$174.85 per ADS, pursuant to the previously disclosed Share Purchase Agreement dated October 31, 2019, as amended, by and between the Company and Amgen (the “Share Purchase Agreement”). Immediately following the share issuance, the Company has a total of 1,007,975,711 outstanding ordinary shares, including 847,184,819 ordinary shares represented by ADSs.





The offer and sale of the securities to be issued pursuant to the Share Purchase Agreement was made in a private placement in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering, and/or Regulation D under the Securities Act. All certificates evidencing the securities will bear a standard restrictive legend under the Securities Act.

Appointment of New Director

Concurrent with the closing of the other transactions described in this Current Report on Form 8-K and following the approval by a majority vote of the Company’s shareholders, on the Effective Date, Mr. Anthony C. Hooper was appointed to serve as a Class III director until the 2022 Annual General Meeting of Shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. Mr. Hooper has not been appointed to any committees of the Board of Directors of the Company as of the date of this Current Report on Form 8-K.
 
Mr. Hooper, aged 65, retired from Amgen in January 2020, where he was Executive Vice President from September 2018 to January 2020, and Executive Vice President, Global Commercial Operations from 2011 to August 2018. From 2010 to 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and Intercontinental of Bristol-Myers Squibb Company (BMS). From 2009 to 2010, Mr. Hooper was President, Americas of BMS. From 2004 to 2009, Mr. Hooper was President, U.S. Pharmaceuticals, Worldwide Pharmaceuticals Group, a division of BMS. Prior to that, Mr. Hooper held various senior leadership positions at BMS. Prior to joining BMS, Mr. Hooper was Assistant Vice President of Global Marketing for Wyeth Laboratories. Mr. Hooper earned law and MBA degrees from the University of South Africa in 1978 and 1988 respectively. Mr. Hooper serves on the board of MannKind Corporation (ticker symbol: MNKD), a company listed on the NASDAQ. We believe Mr. Hooper’s extensive experience and knowledge in the healthcare sector and broad international experience in pharmaceutical commercial operations qualify him to serve on, and contributes to the diversity of, the Board.

Mr. Hooper is a consultant of Amgen.
 
Mr. Hooper will receive the same compensation and indemnification as the Company’s other independent directors, as described in the Company’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2019 and the Current Report on Form 8-K filed with the SEC on June 5, 2019. In accordance with the Company’s amended independent director compensation policy (the “Policy”) and the provisions of the Company’s Second Amended and Restated 2016 Share Option and Incentive Plan, as amended (the “2016 Plan”), the Company will grant Mr. Hooper a share option valued at US$300,000, pro-rated in the first year of service, with an exercise price equal to the greater of (i) the fair market value of the Company’s ordinary shares on the date of grant and (ii) the average fair market value of the Company’s ordinary shares over the five trading days preceding the date of grant, in each case as determined in reference to the closing price of the Company’s ADSs on the NASDAQ Stock Market. One ADS represents 13 ordinary shares. The share option will vest in full on the earlier of the first anniversary of date of grant or the date of the next annual meeting of shareholders, and in full upon death, disability or the occurrence of specified events in connection with a change of control of the Company. Mr. Hooper will also receive annual cash compensation of US$50,000 for his service as a director, pro-rated in the first year of service, and reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board of Directors and its committees. Additionally, Mr. Hooper will be entitled to annual equity grants in accordance with the Policy and the 2016 Plan. 

Pursuant to the Share Purchase Agreement, Amgen has the right to designate a non-executive director to serve on the Board of Directors of the Company until the earlier of (a) the date on which Amgen holds securities representing less than 10% of the then outstanding shares of the Company as a result of Amgen's sale of such securities or Amgen's failure to participate in future offerings and (b) the third anniversary of the date of the expiration or termination of the Collaboration Agreement. Amgen designated Anthony C. Hooper to serve as a non-executive Director on the Board of Director upon the closing of the transactions contemplated by the Share Purchase Agreement and the Collaboration Agreement.

There is no transaction between Mr. Hooper and the Company that would be reportable under Item 404(a) of Regulation S-K.






Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
 
 
 
Exhibit No.
 
Description
99.1
 
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL






Item 9.01. Financial Statements and Exhibits.
 
Exhibit Index
 
 
 
 
Exhibit No.
 
Description
99.1
 
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
BEIGENE, LTD.
 
 
 
 
 
 
Date: January 2, 2020
By: 
/s/ Scott A. Samuels        
 
Name:
Scott A. Samuels
 
Title:
Senior Vice President, General Counsel













 EX-99.1 2 beigeneamgenclosure112.htm EXHIBIT 99.1 Exhibit

BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
•
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene Shares
•
Anthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors
CAMBRIDGE, Mass. and BEIJING, China, Jan. 2, 2020 (GLOBE NEWSWIRE) --BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following approval by its shareholders and satisfaction of other closing conditions, the global strategic oncology collaboration with Amgen (NASDAQ: AMGN), previously announced on October 31, 2019, has become effective and Amgen has completed its purchase of an approximately 20.5% equity stake in BeiGene.
Under the terms of the collaboration, BeiGene will assume responsibility for the commercialization and development in China of Amgen’s three oncology medicines, XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) that have been approved or filed in China. BeiGene and Amgen will collaborate to advance 20 investigational oncology assets in Amgen’s pipeline, with BeiGene leading development and commercialization in China. Amgen purchased 15,895,001 of BeiGene’s American Depositary Shares (representing 206,635,013 ordinary shares) for approximately $2.8 billion in cash.
In addition, BeiGene today announced the election of Anthony C. Hooper, former Executive Vice President of Global Commercial Operations at Amgen, to its board of directors, effective today, pursuant to the terms of the share purchase agreement. Mr. Hooper joined Amgen in October 2011 as Executive Vice President of Global Commercial Operations, a role he held until August 2018, before his recent retirement. Prior to joining Amgen, Mr. Hooper spent more than 15 years at Bristol-Myers Squibb. His last role there was Senior Vice President, Global Commercial Operations and President of the company’s pharmaceutical business in the Americas, Japan and


Intercontinental regions. Previously, Mr. Hooper was assistant vice president of Global Marketing for Wyeth Laboratories and led the international marketing group for Lederle International.
“We are excited to begin delivering on this opportunity to help advance Amgen’s important oncology pipeline and portfolio for patients who may benefit around the world. Through this strategic collaboration with Amgen, we are also pleased to welcome Tony Hooper to our board of directors. Tony’s commitment to patients and his commercial experience with larger organizations will serve us well as BeiGene continues to grow and expand our commercial operations,” said John V. Oyler, Chairman, Co-Founder and CEO of BeiGene.
“BeiGene is uniquely positioned to make a positive impact on both our industry and patients by developing new cancer medicines using a new global model enabled by the recent regulatory reforms in China. Having spent time with the BeiGene team, I’m impressed by their insights, ingenuity and commitment to delivering quality treatments to more people in need,” said Mr. Hooper.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,300 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets BRUKINSA™ (zanubrutinib) and in China, the Company has received approval to market its anti-PD-1 antibody tislelizumab and markets ABRAXANE® (paclitaxel for injection [albumin bound]), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) under a license from Celgene Logistics Sarl, a Bristol-Myers Squibb company, and plans to market XGEVA® (denosumab) under a license from Amgen.1 2 


BeiGene Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s plans and expectations for the further development and potential commercialization of XGEVA, KYPROLIS, BLINCYTO and Amgen’s oncology pipeline assets and the parties’ commitments and the potential benefits of the collaboration. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
1 ABRAXANE® is registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company. 
2 XGEVA® is a registered trademark of Amgen.






Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com

Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com




 EX-101.SCH 3 bgne-20200102.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bgne-20200102_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bgne-20200102_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bgne-20200102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Street Address Entity Address, Address Line One Entity Address, Street Address 2 Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of each class Title of 12(b) Security Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 bgne-20200102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ZIP 8 0001651308-20-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651308-20-000003-xbrl.zip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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Document
Jan. 02, 2020
Cover page.  
Document Type 8-K
Document Period End Date Jan. 02, 2020
Entity Registrant Name BEIGENE, LTD.
Entity Incorporation, State or Country Code E9
Entity File Number 001-37686
Entity Tax Identification Number 98-1209416
Entity Address, Street Address c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address 2 94 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
Entity Address, Country KY
City Area Code 345
Local Phone Number 949-4123
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol BGNE
Name of each exchange on which registered NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001651308
Amendment Flag false
XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Document Sheet http://beigene.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports a8-kx02jan20.htm beigeneamgenclosure112.htm bgne-20200102.xsd bgne-20200102_cal.xml bgne-20200102_def.xml bgne-20200102_lab.xml bgne-20200102_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 a8-kx02jan20_htm.xml IDEA: XBRL DOCUMENT 0001651308 2020-01-02 2020-01-02 false 0001651308 8-K 2020-01-02 BEIGENE, LTD. E9 001-37686 98-1209416 c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY 345 949-4123 false false false false American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share BGNE NASDAQ false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8-kx02jan20.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bgne-20200102_cal.xml" ] }, "definitionLink": { "local": [ "bgne-20200102_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "a8-kx02jan20.htm" ] }, "labelLink": { "local": [ "bgne-20200102_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bgne-20200102_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bgne-20200102.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bgne", "nsuri": "http://beigene.com/20200102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx02jan20.htm", "contextRef": "D2020Q1AMGN", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Document", "role": "http://beigene.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx02jan20.htm", "contextRef": "D2020Q1AMGN", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Street Address" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Street Address 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" }